（详情见文章内容）

暂无相关信息！

[1] BRYCE AH, PIULATS JM, REAUME MN, et al. Rucaparib for metastatic castration- resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy & rucaparib vs docetaxel or second- generation androgen pathway inhibitor therapy [J]. J Clin Oncol, 2023, 41(6): 18. 

[2] AGARWAL N, AZAD A, CARLES J, et al. TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first- line (1L) treatment in patients (pts) with metastatic castration- resistant prostate cancer (mCRPC) [J]. J Clin Oncol, 2023, 41, 6- suppl: LBA17. 

[3] CLARKE NW, ARMSTRONG AJ, THIERY- VUILLEMIN A, et al. Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first- line (1L) therapy for metastatic castration- resistant prostate cancer (mCRPC) [J]. J ClinOncol,2023, 41, 6- suppl:LBA16. 

[4] GALSKY MD, WITJES AA, GSCHWEND JE, et al. Extended follow- up results from the CheckMate 274 trial [J]. J Clin Oncol, 2023, 41, 6-suppl: LBA443. 

[5] GALSKY MD, DANESHMAND S, LEWIS SC, et al. Co- primary endpoint analysis of HCRN GU 16- 257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC) [J]. J Clin Oncol, 2023, 41, 6-suppl: 447. 

[6] BAMIAS A, DAVIS ID, GALSKY MD, et al. Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study [J]. J ClinOncol, 2023, 41, 6- suppl: LBA441. 

[7] ZHENG RS, ZHANG SW, ZENGHM, et al. Cancer incidence and mortality in China, 2016 [J]. J Natl Cancer Cent, 2022, 2(1): 1-9.

王启林.前列腺癌与膀胱癌的治疗热点[J]. 泌尿外科杂志（电子版）,2023,15(4):1-2. DOI:10.20020/j.CNKI.1674-7410.2023.04.01

暂无相关信息！

暂无相关信息！

暂无相关信息！

暂无相关信息！

暂无相关信息！

暂无相关信息！